Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster; Mary Pat Bartoszek; Colleen O'connell; David Pitt; Michael Racke

doi:10.1177/1756285611422108

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster, Mary Pat Bartoszek, Colleen O'connell, David Pitt, Michael Racke

Résultat de recherche: Review article › examen par les pairs

40 Citations (Scopus)

Résumé

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

Langue d'origine	English
Pages (de-à)	319-332
Nombre de pages	14
Journal	Therapeutic Advances in Neurological Disorders
Volume	4
Numéro de publication	5
DOI	https://doi.org/10.1177/1756285611422108
Statut de publication	Published - sept. 2011
Publié à l'externe	Oui

Note bibliographique

Funding Information:
This work was supported by NINDS (grant number RO1 NS 037513 to MKR).

ASJC Scopus Subject Areas

Pharmacology
Neurology
Clinical Neurology

Accès au document

10.1177/1756285611422108

Autres fichiers et liens

Citer

@article{7ee63df992e849b4985a0d168c0241fd,

title = "Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis",

abstract = "The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.",

author = "Aaron Boster and Bartoszek, {Mary Pat} and Colleen O'connell and David Pitt and Michael Racke",

note = "Funding Information: This work was supported by NINDS (grant number RO1 NS 037513 to MKR). ",

year = "2011",

month = sep,

doi = "10.1177/1756285611422108",

language = "English",

volume = "4",

pages = "319--332",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

AU - Boster, Aaron

AU - Bartoszek, Mary Pat

AU - O'connell, Colleen

AU - Pitt, David

AU - Racke, Michael

N1 - Funding Information: This work was supported by NINDS (grant number RO1 NS 037513 to MKR).

PY - 2011/9

Y1 - 2011/9

N2 - The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

AB - The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

UR - http://www.scopus.com/inward/record.url?scp=80053327895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053327895&partnerID=8YFLogxK

U2 - 10.1177/1756285611422108

DO - 10.1177/1756285611422108

M3 - Review article

AN - SCOPUS:80053327895

SN - 1756-2856

VL - 4

SP - 319

EP - 332

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 5

ER -

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Résumé

Note bibliographique

ASJC Scopus Subject Areas

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer